Stock Research for BIOYF

Current Price


Latest Update: 2018-02-14 13:48:00

$ 7.0900
$ 7.0886
$ 7.0900

Featured Broker: TradeStation

Get the due diligence for another stock.


BIOYF Stock Chart & Research Data

The BIOYF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BIOYF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


BIOYF Due diligence Resources & Stock Charts

The BIOYF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BIOYF Detailed Price Forecast - CNN Money CNN View BIOYF Detailed Summary - Google Finance
Yahoo View BIOYF Detailed Summary - Yahoo! Finance Zacks View BIOYF Stock Research & Analysis -

Stock Analysis

TradeIdeas View BIOYF Trends & Analysis - Trade-Ideas Barrons View BIOYF Major Holders - Barrons
NASDAQ View BIOYF Call Transcripts - NASDAQ Seeking View BIOYF Breaking News & Analysis - Seeking Alpha
Spotlight View BIOYF Annual Report - OTC Report View BIOYF OTC Short Report -
TradeKing View BIOYF Fundamentals - TradeKing Charts View BIOYF SEC Filings - Bar Chart
WSJ View Historical Prices for BIOYF - The WSJ Morningstar View Performance/Total Return for BIOYF - Morningstar
MarketWatch View the Analyst Estimates for BIOYF - MarketWatch CNBC View the Earnings History for BIOYF - CNBC
StockMarketWatch View the BIOYF Earnings - StockMarketWatch MacroAxis View BIOYF Buy or Sell Recommendations - MacroAxis
Bullish View the BIOYF Bullish Patterns - American Bulls Short Pains View BIOYF Short Pain Metrics -

Social Media Mentions

StockTwits View BIOYF Stock Mentions - StockTwits PennyStocks View BIOYF Stock Mentions - PennyStockTweets
Twitter View BIOYF Stock Mentions - Twitter Invest Hub View BIOYF Investment Forum News - Investor Hub
Yahoo View BIOYF Stock Mentions - Yahoo! Message Board Seeking Alpha View BIOYF Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for BIOYF - Insider Cow View Insider Transactions for BIOYF - Insider Cow
CNBC View BIOYF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BIOYF - OTC Markets
Yahoo View Insider Transactions for BIOYF - Yahoo! Finance NASDAQ View Institutional Holdings for BIOYF - NASDAQ

Stock Charts

FinViz View BIOYF Stock Insight & Charts - StockCharts View BIOYF Investment Charts -
BarChart View BIOYF Stock Overview & Charts - BarChart Trading View View BIOYF User Generated Charts - Trading View

Latest Financial News for BIOYF

Should You Buy BioSyent Inc (CVE:RX)?
Posted on Thursday February 08, 2018

BioSyent Inc (TSXV:RX), a pharmaceuticals company based in Canada, saw significant share price volatility over the past couple of months on the TSXV, rising to the highs of CA$10.38 andRead More...

BioSyent, Inc. : Neutral price; Buy/ Sell depends on fundamentals
Posted on Monday December 04, 2017

Categories: Yahoo FinanceBioSyent, Inc. relative valuation is now NEUTRAL. It was previously rated UNDERVALUED, and has a fundamental analysis score of 88. Our analysis is based on comparing BioSyent, Inc. with the following peers – Omeros Corporation, Oncolix, Inc., Onconova Therapeutics Inc. and OncoMed Pharmaceuticals, Inc. (OMER-US, ONCX-US, ONTX-US and OMED-US). Relative Valuation BioSyent, Inc. is currently ... Read more (Read more...)

BioSyent, Inc. : A good buy now? Relative to peers, maybe.
Posted on Monday August 07, 2017

Categories: Yahoo FinanceBioSyent, Inc. relative valuation is now UNDERVALUED. It was previously rated OVERVALUED, and has a fundamental analysis score of 82. Our analysis is based on comparing BioSyent, Inc. with the following peers – Ohr Pharmaceutical, Inc., Omni Bio Pharmaceutical, Inc., OncoMed Pharmaceuticals, Inc. and OrganiGram Holdings Inc (OHRP-US, OMBP-US, OMED-US and OGRMF-US). Relative Valuation BioSyent, ... Read more (Read more...)

BioSyent, Inc. :BIOYF-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017
Posted on Tuesday June 06, 2017

Categories: Yahoo FinanceGet free summary analysis BioSyent, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of BioSyent, Inc. – Omeros Corporation, Onconova Therapeutics Inc., Ono Pharmaceutical Co., Ltd. Unsponsored ADR and OncoMed Pharmaceuticals, Inc. (OMER-US, ONTX-US, OPHLY-US and OMED-US) that have also reported for this ... Read more (Read more...)

BioSyent Announces Changes to Its Board of Directors
GlobeNewswire (press release) - Jan 8, 2018
Mr. Andrews holds an Honours B.Sc. from Memorial University. Mr. Andrews recently served as a Board Director for GMD Distribution Inc., a logistics service provider for the life sciences industry, which was acquired by McKesson Canada in 2017. BioSyent ...

BioSyent Inc.
MarketWatch - Sep 15, 2012
BioSyent, Inc. is a specialty pharmaceutical company. It operates through its wholly owned subsidiaries, BioSyent Pharma, Inc. and Hedley Technologies Ltd.

BioSyent Schedules Q3 2017 Earnings Release for November 15, 2017
GlobeNewswire (press release) - Nov 8, 2017
TORONTO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) will be reporting its financial results for the three and nine months ended September 30, 2017 on Wednesday, November 15, 2017 at 8:00am (ET).

$0.09 EPS Expected for BioSyent Inc. (RX)
BZ Weekly - Feb 18, 2018
Analysts expect BioSyent Inc. (CVE:RX) to report $0.09 EPS on March, 21.They anticipate $0.01 EPS change or 12.50 % from last quarter's $0.08 EPS.

Enter a stock symbol to view the stock details.